Stephanie van Hoppe

97 ABCB1 restricts brain penetration of the BTK inhibitor ibrutinib while CYP3A limits its oral bioavailability Supplemental Figure 9 - Ibrutinib-DiOH (DiOH) to ibrutinib concentration ratios in the liver ( A ), spleen ( B ), kidney ( C ) and plasma ( D & E ) in female WT (black circles), Cyp3a -/- (blue squares), Cyp3aXA (peach triangles), Cyp3aXV (red triangles) and Cyp3aXAV (maroon diamonds) mice 20 minutes after oral administration of 10 mg/kg ibrutinib. *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared to WT mice. Data are given as mean ± SD. n = 5−6 mice per group. Supplemental Figure 9. Ibrutinib-DiOH (DiOH) to ibrutinib concentratio ratios in the liver ( A ), spleen ( B ), kidney ( C ) and plasma ( D & E ) in female WT (black circles), Cyp3a -/- (blue squares), Cyp3aXA (peach triangles), Cyp3aXV (red triangles) and Cyp3aXAV (maroon diamonds) mice 20 minutes after oral administration of 10 mg/kg ibrutinib. *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared to WT mice. Data are given as mean ± SD. n = 5−6 mice per group.